These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8928243)

  • 61. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
    Beisland HO; Binkowitz B; Brekkan E; Ekman P; Kontturi M; Lehtonen T; Lundmo P; Pappas F; Round E; Shapiro D
    Eur Urol; 1992; 22(4):271-7. PubMed ID: 1283370
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Proscar: five-year experience.
    Moore E; Bracken B; Bremner W; Geller J; Imperato-McGinley J; McConnell J; Roy J; Tenover L; Vaughan D; Pappas F
    Eur Urol; 1995; 28(4):304-9. PubMed ID: 8575497
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study].
    Sökeland J; Albrecht J
    Urologe A; 1997 Jul; 36(4):327-33. PubMed ID: 9340898
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.
    Edwards JE; Moore RA
    BMC Urol; 2002 Dec; 2():14. PubMed ID: 12477383
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.
    Tenover JL; Pagano GA; Morton AS; Liss CL; Byrnes CA
    Clin Ther; 1997; 19(2):243-58. PubMed ID: 9152564
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride].
    Tarasov NI; Izmaĭlov RI
    Urologiia; 2009; (5):40-5. PubMed ID: 20209869
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group.
    Nickel JC
    Br J Urol; 1998 Mar; 81(3):383-7. PubMed ID: 9523656
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia.
    Lowe FC; McConnell JD; Hudson PB; Romas NA; Boake R; Lieber M; Elhilali M; Geller J; Imperto-McGinely J; Andriole GL; Bruskewitz RC; Walsh PC; Bartsch G; Nacey JN; Shah S; Pappas F; Ko A; Cook T; Stoner E; Waldstreicher J;
    Urology; 2003 Apr; 61(4):791-6. PubMed ID: 12670567
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The effects of mepartricin on the symptomatology of prostatic hypertrophy--double-blind controlled trial].
    Vanden Bossche M; Abi Aad A; Vandendris M; Van Cangh P; Schulman C
    Acta Urol Belg; 1991; 59(1):93-104. PubMed ID: 1718154
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1995 Oct; 154(4):1466-9. PubMed ID: 7544845
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia.
    Sullivan MJ; Geller J
    BMC Urol; 2002; 2():2. PubMed ID: 11818031
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?
    Mondaini N; Gontero P; Giubilei G; Lombardi G; Cai T; Gavazzi A; Bartoletti R
    J Sex Med; 2007 Nov; 4(6):1708-12. PubMed ID: 17655657
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.
    Wessells H; Roy J; Bannow J; Grayhack J; Matsumoto AM; Tenover L; Herlihy R; Fitch W; Labasky R; Auerbach S; Parra R; Rajfer J; Culbertson J; Lee M; Bach MA; Waldstreicher J;
    Urology; 2003 Mar; 61(3):579-84. PubMed ID: 12639651
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effect of low dose finasteride therapy in a man with prostatism.
    Sullivan MJ; Smith RC
    J Urol; 1996 Feb; 155(2):652. PubMed ID: 8558692
    [No Abstract]   [Full Text] [Related]  

  • 75. Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group.
    Stoner E; Round E; Ferguson D; Gormley GJ
    J Urol; 1994 May; 151(5):1296-300. PubMed ID: 7512661
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride.
    Stamatiou KN; Zaglavira P; Skolarikos A; Sofras F
    Int Braz J Urol; 2008; 34(5):555-61; discussion 561-2. PubMed ID: 18986558
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride.
    Geller J
    Eur Urol; 1995; 27(4):267-73. PubMed ID: 7544731
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Improvement in androgenetic alopecia in 53-76-year-old men using oral finasteride.
    Brenner S; Matz H
    Int J Dermatol; 1999 Dec; 38(12):928-30. PubMed ID: 10632776
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Changes in the echostructure of prostatic adenomas during drug therapy].
    Szutrely HP
    Med Klin Prax; 1982 Aug; 77(18):42-6. PubMed ID: 6182449
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Changes in HDL-cholesterol and lipoprotein Lp(a) after 6-month treatment with finasteride in males affected by benign prostatic hyperplasia (BPH).
    Denti L; Pasolini G; Cortellini P; Sanfelici L; Benedetti R; Cecchetti A; Ferretti S; Bruschieri L; Ablondi F; Valenti G
    Atherosclerosis; 2000 Sep; 152(1):159-66. PubMed ID: 10996351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.